GlassScriptPhysician profile
Taylor R Hendon
NPI 1588019772
$10,733.55
in general payments reported to CMS, 2019-2025
31 companies · $813 in 2025
The $813 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,906 · 2022: $1,795 · 2023: $3,048 · 2024: $3,172 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,033 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,032.59 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,811.61 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Mannkind Corporation | $1,523.28 | 2021-2025 | Afrezza |
| Lilly USA, LLC | $1,406.86 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,183.46 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Insulet Corporation | $803.70 | 2021-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.90 | 2021-2025 | Jardiance, Synjardy |
| Xeris Pharmaceuticals, INC. | $381.58 | 2023-2025 | Gvoke Hypopen |
| Medtronic, INC. | $367.69 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Cequr Corporation | $362.74 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $348.05 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $334.70 | 2023-2025 | |
| Amgen INC. | $224.42 | 2023-2025 | Repatha, Repatha |
| Beta Bionics, INC. | $210.60 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $150.92 | 2021-2024 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $116.67 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $93.48 | 2022-2024 | Unithroid |
| Amphastar Pharmaceuticals, INC. | $81.98 | 2024 | |
| Abbvie INC. | $77.94 | 2022-2024 | |
| Ibsa Pharma INC. | $77.33 | 2023-2024 | Tirosint, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.06 | 2022 | |
| Ascensia Diabetes Care US INC. | $70.47 | 2023 | |
| Corcept Therapeutics | $52.28 | 2024 | Korlym |
| Nevro Corp. | $36.95 | 2023-2024 | Senza |
| Sequel Med Tech, LLC | $27.68 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $26.56 | 2025 | Yorvipath |
| Bigfoot Biomedical INC | $26.16 | 2023 | Unity Diabetes Management System |
| Kyowa Kirin, INC. | $25.12 | 2023 | Crysvita |
| Acella Pharmaceuticals, LLC | $21.53 | 2025 | NP Thyroid 60 |
| Halozyme INC | $18.61 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.04 | 2024 | Farxiga |
| Esperion Therapeutics, INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Hendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.